Astellas Aims for Global Oncology Position through OSI
By PharmaDeals Analyst
Pharma Deals Review: Vol 2010 Issue 3 (Table of Contents)
Published: 31 Mar-2010
DOI: 10.3833/pdr.v2010.i3.1323 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered?
Please login using the top left purple box.
Copyright: © IQVIA 2018
Astellas Pharma made a second attempt to enter the US market to build a world class oncology platform making a tender offer to acquire shares of New York-based OSI Pharmaceuticals for USD 52 per share in cash, amounting to USD 3...